Printer Friendly

GENSIA INITIATES PHASE 2 CLINICAL TRIAL WITH ARASINE IN NON-CARDIAC SURGERY

 GENSIA INITIATES PHASE 2 CLINICAL TRIAL
 WITH ARASINE IN NON-CARDIAC SURGERY
 SAN DIEGO, March 30 /PRNewswire/ -- Gensia Pharmaceuticals Inc. (NASDAQ: GNSA) today announced that is has initiated a Phase 2 clinical trial with Arasine(TM) in patients undergoing major non-cardiac surgery who are at high risk of developing cardiovascular complications. The purpose of this Phase 2 dose escalation study is to investigate dosing regimens for Arasine in non-cardiac surgery. The company plans to begin a multi-center Phase 3 clinical trial with Arasine in non-cardiac surgery patients in the United States, Canada and Western Europe in the last half of 1992, according to David F. Hale, chairman, president and chief executive officer.
 Recent clinical reports indicate that up to 3 million people with known or suspected coronary disease undergo major non-cardiac surgery every year in the United States. According to these clinical reports, up to 18 percent of high-risk patients suffer serious adverse cardiovascular events associated with non-cardiac surgery. These adverse cardiovascular events include cardiac death, myocardial infarction (heart attack), serious arrhythmias and congestive heart failure.
 "These patients typically have known or suspected coronary artery disease and are undergoing major procedures such as vascular or abdominal surgery and hip replacements," said Hale. "We believe Arasine may reduce the incidence of heart attacks and other adverse cardiovascular events in these high-risk patients."
 Gensia is currently investigating Arasine in Phase 3 clinical trials in patients undergoing coronary artery bypass surgery. Based on a Phase 2 clinical trial in coronary artery bypass surgery completed in 1991, Arasine appears to reduce the incidence of myocardial infarction and other adverse cardiovascular events associated with the surgery.
 Gensia plans to complete its Phase 3 clinical trials with Arasine in coronary artery bypass surgery in April 1992 with enrollment of approximately 1,200 patients. United States, European and Canadian regulatory filings for the use of Arasine in this indication are planned between September and December of 1992.
 Gensia Pharmaceuticals is a San Diego-based biopharmaceutical company formed to discover, develop, manufacture and market novel pharmaceutical products for the treatment and diagnosis of human diseases.
 -0- 3/30/92
 /CONTACT: David F. Hale, chairman, president and CEO, or Martha L. Hough, of Gensia Pharmaceuticals, 619-546-8300/
 (GNSA) CO: Gensia Pharmaceuticals Inc. ST: California IN: MTC SU:


DM-JL -- SD003 -- 2722 03/30/92 09:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 30, 1992
Words:384
Previous Article:AMERICA'S CUP SAILBOAT AT COORS TODAY
Next Article:WORK RECOVERY INC. ANNOUNCES OPENING OF THREE WORK RECOVERY CENTERS
Topics:


Related Articles
GENSIA ANNOUNCES COMPLETION OF ARASINE PHASE 3 TRIAL
ARBUTAMINE CLINICAL AND PRECLINICAL DATA ABSTRACTS PUBLISHED IN CIRCULATION
GENSIA TO PROCEED AS PLANNED WITH ARASINE REGULATORY FILINGS IN UNITED STATES AND EUROPE
GENSIA FILES NDA FOR ARASINE AS PLANNED WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA)
GENSIA FILES REGULATORY SUBMISSIONS FOR ARASINE AS PLANNED IN EUROPEAN MARKETS
RIBI IMMUNOCHEM: STUDY TO DETERMINE ABILITY OF MPL(R)-C TO REDUCE HEART MUSCLE DAMAGE ASSOCIATED WITH BYPASS SURGERY
GENSIA AND ARAMED INITIATE PHASE 1 WITH ARA COMPOUND
GENSIA ANNOUNCES DATA FROM MULTICENTER STUDY WITH PROTARA IN CORONARY ARTERY BYPASS SURGERY
GENSIA INITIATES PHASE 1 CLINICAL TRIAL WITH GP3269
Action Pharma in new Phase II Clinical Trial.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters